Ranibizumab biosimilar (Samsung Bioepis)

雷珠单抗生物类似药（Samsung Bioepis）

Report date: 2025/07/22 11:21:15

Base Information

Drug NameRanibizumab biosimilar (Samsung Bioepis)
Drug Alias Nameranibizumab-nunaBYOOVIZAmelivuSB-11SB11 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[7] 
Global Approved IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/08/18
Country/TerritoryCzechiaUnited StatesSingapore +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncSamsung Bioepis Nl BvSamsung Bioepis Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeS01LA04
Related LinksN/A